

References

1. Cervantes F. How I treat myelofibrosis. *Blood*. 2014;124(17):2635-2642.
2. Daver N, Cortes J, Newberry K, et al. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. *Haematologica*. 2015;100(8):1058-1063.
3. Stegelmann F, Koschmiede S, Isfort S, et al. Updated results from the German MpnsG-0212 combination trial: Ruxolitinib plus pomalidomide in myelofibrosis with anemia. Presented at: the 2019 ASH Annual Meeting & Exposition; December 7-10, 2019; Orlando, FL. Abstract 672.
4. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. Ruxolitinib plus pomalidomide combination therapy in patients with primary and secondary MF (POMINC). Available at: <https://clinicaltrials.gov/ct2/show/NCT01644110?term=pomalidomide&cntry=DE&draw=2&rank=4>. Accessed October 6, 2020.
5. Talpaz M, Rampal R, Verstovsek S, et al. CPI-0610, A Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, as Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update From Phase 2 MANIFEST Study. EHA25 Virtual. Abstract: EP1091
6. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. A phase 2 study of CPI-0610 with and without ruxolitinib in patients with myelofibrosis. Available at: <https://clinicaltrials.gov/ct2/show/NCT02158858?term=CPI-0610&draw=2&rank=4>. Accessed October 6, 2020.
7. US Food and Drug Administration. FDA approves first therapy to treat patients with rare blood disorder [press release]. November 8, 2019. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder>. Accessed October 6, 2020.
8. US Food and Drug Administration. FDA approves luspatercept-aamt for anemia in adults with MDS [press release]. April 3, 2020. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds>. Accessed October 6, 2020.
9. Suragani RNVS, Cadena SM, Cawley SM, et al. Transforming growth factor- β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. *Nat Med*. 2014;20(4):408-414.
10. Gerds AT, Vannucchi AM, Passamonti F, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Presented at: the 2019 ASH Annual Meeting & Exposition; December 7-10, 2019; Orlando, FL. Abstract 557.
11. Bose P, Pemmaraju N, Masarova L, et al. Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study. *Blood*. 2020;136 (Supplement 1):10-11. Available at: <https://doi.org/10.1182/blood-2020-140441>. Accessed November 6, 2020.
12. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. Sotatercept in treating patients with myeloproliferative neoplasm-associated myelofibrosis or anemia. Available at: <https://clinicaltrials.gov/ct2/show/NCT01712308?term=NCT01712308&draw=2&rank=1>. Accessed October 6, 2020.

13. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. A study of momelotinib versus danazol in symptomatic and anemic myelofibrosis patients (MOMENTUM). Available at: <https://clinicaltrials.gov/ct2/show/NCT04173494?term=momelotinib&phase=2&draw=2&rank=1>. Accessed October 6, 2020.
14. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. INCB000928 administered as a monotherapy or in combination with ruxolitinib in participants with anemia due to myeloproliferative disorders. Available at: <https://clinicaltrials.gov/ct2/show/NCT04455841?term=INCB00928&draw=2&rank=1>. Accessed October 6, 2020.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloproliferative neoplasms. Version 1.2020 — May 21, 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed October 7, 2020.
16. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med*. 2004;350(2):114-124.
17. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med*. 2013;368(1):22-33.
18. Kaplan ME, Mack K, Goldberg D, Donovan PB, Berk PD, Wasserman R. Long-term management of polycythemia vera with hydroxyurea: A progress report. *Semin Hematol*. 1986;23(3):167-171.
19. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. *Semin Hematol*. 1997;34(1):17-23.
20. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood*. 2005;105(7):2664-2667.
21. FDA accepts application for ropeginterferon alfa-2b for polycythemia vera [press release]. Available at: <https://www.onclive.com/view/fda-accepts-application-for-ropeginterferon-alfa2b-for-polythycemia-vera>. Accessed October 7, 2020.
22. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2b induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood*. 112(8):3065-3072.
23. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocytopenia receiving pegylated interferon alpha-2b. *Blood*. 2013;122(6):893-901.
24. Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2b in patients with essential thrombocytopaenia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. *Lancet Haematol*. 2017;4(4):e165-e175.
25. Huang BT, Zeng QC, Zhao WH, et al. Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocytopenia and polycythemia vera with JAKV617F positive mutation. *Leuk Res*. 2014;38(10):1177-1183.
26. Verger E, Cassinat B, Chaveau A, et al. Clinical and molecular response to interferon-alpha therapy in essential thrombocytopenia patients with CALR mutations. *Blood*. 2015;126(24):2585-2591.
27. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. Hepcidin mimetic in patients with polycythemia vera. Available at:

- <https://clinicaltrials.gov/ct2/show/NCT04057040?term=hepcidin&cond=Polycythemia+Vera&draw=2&rank=1>. Accessed October 7, 2020.
28. Barbui T, Vannucchi AM, De Stefano V, et al. Phase II randomized clinical trial comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera. Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress; June 2020. Abstract LBA2602.
29. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. The benefit/risk profile of AOP2014 in low risk patients with PV (low-PV). Available at: <https://clinicaltrials.gov/ct2/show/NCT03003325?term=interferon&cond=Polycythemia+low+risk&draw=2&rank=1>. Accessed October 7, 2020.
30. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. KRT-232 in subjects with PMF, post-PV MF, or post-ET MF who have failed a JAK inhibitor. Available at: <https://clinicaltrials.gov/ct2/show/NCT03662126?term=MDM-2&cond=Polycythemia+Vera&draw=2&rank=3>. Accessed October 7, 2020.
31. National Institutes of Health, US National Library of Medicine, ClinicalTrials.gov Website. KRT-232 compared to ruxolitinib in patients with phlebotomy-dependent polycythemia vera. Available at: <https://clinicaltrials.gov/ct2/show/NCT03669965?term=MDM-2&cond=Polycythemia+Vera&draw=2&rank=1>. Accessed October 7, 2020.